Updates from the 2025 ASCO Annual Meeting
The American Society of Clinical Oncology Annual Meeting is the largest cancer conference in the world.
PCF Chief Medical Office Dr. Phillip Koo and urologic oncologist Dr. Zachary Klaassen have an informal discussion of critical prostate cancer updates from ASCO. Learn about:
- Localized disease: A new treatment combination (CAN-2409 + valacyclovir) with radiation therapy in localized prostate cancer
- Recurrence: Enzalutamide + hormone therapy OR enzalutamide alone improved patient outcomes, regardless of initial treatment
- Metastatic hormone-sensitive disease:
- New approval for darolutamide
- Darolutamide is linked to better quality of life vs. hormone therapy alone
- Promising results of the combination of niraparib + abiraterone
- Exercise lengthens life in colon cancer. How might this apply to prostate cancer?